0001628280-24-027720.txt : 20240611
0001628280-24-027720.hdr.sgml : 20240611
20240611182628
ACCESSION NUMBER: 0001628280-24-027720
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240607
FILED AS OF DATE: 20240611
DATE AS OF CHANGE: 20240611
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Stein Jeffrey
CENTRAL INDEX KEY: 0001478831
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36912
FILM NUMBER: 241037043
MAIL ADDRESS:
STREET 1: 6310 NANCY RIDGE DRIVE, SUITE 101
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cidara Therapeutics, Inc.
CENTRAL INDEX KEY: 0001610618
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 461537286
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6310 NANCY RIDGE DRIVE
STREET 2: SUITE 101
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-752-6170
MAIL ADDRESS:
STREET 1: 6310 NANCY RIDGE DRIVE
STREET 2: SUITE 101
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: K2 THERAPEUTICS, INC.
DATE OF NAME CHANGE: 20140611
4
1
wk-form4_1718144781.xml
FORM 4
X0508
4
2024-06-07
0
0001610618
Cidara Therapeutics, Inc.
CDTX
0001478831
Stein Jeffrey
6310 NANCY RIDGE DRIVE, STE 101
SAN DIEGO
CA
92121
1
1
0
0
President & CEO
0
Common Stock
2024-06-07
4
P
0
8000
13.21
A
24580
I
By trust
Common Stock
57884
D
Common Stock
2100
I
By son
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.05 to $13.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
The number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024.
Includes 200 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 20, 2024.
/s/ Shane Ward, Attorney-in-Fact
2024-06-11